戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 l/g (gadoterate meglumine), and 0.07 nmol/g (gadoteridol).
2 rior to administration of the second dose of gadoteridol.
3 st agent leakage correction for imaging with gadoteridol.
4 ased sharply for both agents-but more so for gadoteridol.
5  cartilage with the nonionic contrast agent, gadoteridol.
6 chnique by using a mean dose of 0.18 mmol/kg gadoteridol.
7 differences were not seen in the presence of gadoteridol.
8 ng a single breath hold, enhanced with 30 mL gadoteridol.
9 adolinium species found in rats treated with gadoteridol.
10 d with the macrocyclic agents gadobutrol and gadoteridol.
11 ere obtained after right atrial injection of gadoteridol (0.025 mmol/kg) with an MRI inversion recove
12 f pregnancy, the macaques were injected with gadoteridol (0.1 mmol per kilogram of maternal weight).
13 us injection of gadopentetate dimeglumine or gadoteridol (0.1 mmol/kg), nine images were acquired at
14     Macrocyclic agents were lower at 5 days (gadoteridol, 2.6 nmol/g [1.2]; gadobutrol, 2.7 nmol/g [1
15 obutrol, 16.4 [1.6]; gadoterate, 14.3 [1.6]; gadoteridol, 22.2 [1.8]; gadodiamide, 17.9 [1.4]).
16  either gadodiamide, gadobutrol, gadoterate, gadoteridol (8 x 0.6 mmol per kilogram of body weight),
17 adobutrol, 9.7 [1.2]; gadoterate, 9.2 [1.2]; gadoteridol, 9.9 [1.3]; gadodiamide, 10.5 [1.2]) or 5 we
18 1.2]) and efficiently cleared after 5 weeks (gadoteridol, -95%; gadobutrol and gadoterate, -96%).
19 n addition, we found that the small molecule gadoteridol accumulates around and within ablated tissue
20 usion Compared with other macrocyclic GBCAs, gadoteridol administration led to the lowest level of re
21 magnetic resonance imaging after intravenous gadoteridol administration.
22 ation of the CA4+ partition with that of the gadoteridol affords CA4+ attenuations that significantly
23 -based CA4+) and non-ionic (gadolinium-based gadoteridol) agents.
24 age the distribution inside mouse kidneys of gadoteridol, an exogenous magnetic resonance contrast ag
25 roxyethylcellulose gel (semen simulant) with gadoteridol and dosed via artificial phallus after simul
26  were derived from perfusion MR imaging with gadoteridol and ferumoxytol in 19 patients with apparent
27 lic gadolinium-based contrast agents (GBCAs) gadoteridol and gadoterate meglumine in a pediatric coho
28 g value of real-time imaging with co-infused gadoteridol and putative therapeutic agents (i.e., AAV2-
29 ased contrast agents (GBCAs) gadodiamide and gadoteridol and to quantify the amount of intact gadolin
30 1 mmol/kg) of macrocyclic GBCAs (gadobutrol, gadoteridol, and gadoterate meglumine), linear GBCAs (ga
31 /kg doses of gadodiamide, gadopentetate, and gadoteridol; and a 6-mL/kg dose of saline.
32 n the corresponding regions of AAV2-GDNF and gadoteridol co-infusion or surrounding regions over long
33                                              Gadoteridol comprised 100% of the gadolinium species fou
34 dinated CA4 + and non-ionic gadolinium-based gadoteridol contrast agents into ex vivo bovine medial t
35 T identifies noteworthy correlations between gadoteridol diffusion and biomechanical parameters.
36 o be a good prognostic biomarker, and unlike gadoteridol, does not require contrast agent leakage cor
37 luoroscopically triggered 3D MR angiography (gadoteridol dose range, 0.1-0.3 mmol per kilogram of bod
38  tissue) 50 days after administration of one gadoteridol dose.
39 issue after maternal exposure to intravenous gadoteridol during pregnancy.
40 of 28 078 patients who underwent intravenous gadoteridol-enhanced MR imaging from July 2007 to Decemb
41 dimensional MR angiograms were obtained with gadoteridol enhancement, breath holding, and a three-dim
42 2022, 32 rats received a dose of gadoterate, gadoteridol, gadobutrol, or gadobenate (2.0 mmol/kg) for
43 high rCBV with ferumoxytol and low rCBV with gadoteridol had an mOS of 171 days.
44                   Conclusion The presence of gadoteridol in the amniotic fluid after maternal injecti
45             The presence of gadopentetate or gadoteridol in the blood did not affect measurement of s
46 sues after in utero exposure to two doses of gadoteridol, indicating that a very small amount of gado
47 ons (52 infusions in total) of AAV2-GDNF and gadoteridol (infusion volume, 450 mL per putamen).
48 ue (95% confidence interval [CI]: 0, 0.2) in gadoteridol-injected rats, 1.6 mug gadolinium per gram o
49                     The localization of the [Gadoteridol+K](+) adduct as revealed through DESI-MS com
50 ns and vasculature from the localization of [Gadoteridol+K](+) and [Gadoteridol+Na](+) adducts, respe
51  the localization of [Gadoteridol+K](+) and [Gadoteridol+Na](+) adducts, respectively.
52  (MR) imaging after intravenous injection of gadoteridol (nonionic contrast agent; n = 6) or gadopent
53 ate, gadoxetate, gadobutrol, gadoterate, and gadoteridol) or saline over 4 weeks.
54 clic GBCA (gadobutrol, gadoterate meglumine, gadoteridol), or saline.
55            Concurrent evaluation of CA4+ and gadoteridol partitions in cartilage is accomplished usin
56 contrast, administration of gadopentetate or gadoteridol produced no significant change in serum calc
57 rocyclic contrast agents (gadoteric acid and gadoteridol) produced a maximum stimulation of fibroblas
58                                         With gadoteridol, rCBV was low in 14 (74%) patients, with mOS
59 teoglycans) and a non-ionic gadolinium-based gadoteridol (reflecting water content) contrast agents i
60     DECT lacks significant correlations with gadoteridol-related parameters, while PCD-CT identifies
61 adolinium concentrations for gadodiamide and gadoteridol, respectively, were 0.317 mug/g +/- 0.060 (s
62                                              Gadoteridol resulted in greater visibility of the physis
63 grown in mice were subjected to CA-MSI using Gadoteridol revealing tumor margins and vasculature from
64 0-401 nmol/g; P value range, .001-.70), with gadoteridol showing the lowest level of retention.
65 ncement ratios were significantly higher for gadoteridol than for gadopentetate dimeglumine in the ph
66 ed VY-AADC01 bilaterally coadministered with gadoteridol to the putamen using intraoperative magnetic
67            We found that the accumulation of gadoteridol was enhanced in tumors treated with temperat
68                                   Conclusion Gadoteridol was far less retained, and the entire detect
69        The observed adverse reaction rate to gadoteridol was lower than previously reported.
70 ive-minute MR renography with a 3-mL dose of gadoteridol was performed instead of a routine test-dose
71                                              Gadoteridol was present in the fetoplacental circulation
72 en leakage correction was applied, rCBV with gadoteridol was significantly associated with survival (
73 f AAV2-GDNF with a surrogate imaging tracer (gadoteridol) was used to track infusate distribution dur
74 ved gadolinium (Gd)-based MR contrast agent, gadoteridol, was encapsulated within nanometer-sized pho